Fosun Pharma Competitors and Similar CompaniesClear all

Fosun Pharma's competitors and similar companies include AvKARE, Dompe and Pharmanutra.

	Fosun Pharma Fosun Pharma is a healthcare group operating in a variety of healthcare sectors including pharmaceutical research, development, and manufacturing, healthcare services, medical diagnosis and devices, as well as pharmaceutical distribution and retail.	AvKARE AvKARE is a company engaged in the supply of pharmaceuticals, medical and surgical supplies, and laboratory materials.	Dompe Dompe is a biopharmaceutical company engaged in research, development, and production of therapeutic solutions.	Pharmanutra Pharmanutra, a pharmaceutical company, engages in the research, design, development, and marketing of nutraceutical supplements and medical devices.
Founding Date	Founding Date 1994	Founding Date 2007	Founding Date 1940	Founding Date 2003
Type	Type Public	Type Subsidiary	Type Private	Type Public
Tags	Tags Healthcare biotech distribution medical devices medical diagnostics pharma	Tags Healthcare ecommerce pharma	Tags Healthcare biotech cosmetics distribution drug development medical devices pharma supplements	Tags Healthcare biotech distribution drug development medical devices pharma
Locations	Locations Shanghai, CN HQ	Locations Pulaski, US HQ	Locations Milano, IT HQ Tiranë, AL L'aquila, IT Napoli, IT Boston, US see more	Locations Pisa, IT HQ Pisa, IT
Employees	Employees 40,557	Employees 861% increase	Employees 1,0411% increase	Employees 118
Valuation ($)	Valuation ($) 8.8 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 589.3 m
Financial
Revenue (est.)	Revenue (est.) ¥28.4b (FY, 2019)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) €115.5m (FY, 2024)
Cost of goods	Cost of goods ¥11.5b (FY, 2019)	Cost of goods N/A	Cost of goods N/A	Cost of goods €6.4m (FY, 2024)
Gross profit	Gross profit ¥16.8b (FY, 2019)	Gross profit N/A	Gross profit N/A	Gross profit €110.5m (FY, 2024)
Net income	Net income ¥3.7b (FY, 2019)	Net income N/A	Net income N/A	Net income €16.6m (FY, 2024)